SLNO Q4 2023 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$14M

Net Income

-$11M

EPS (Diluted)

$-0.43

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$181M

Total Liabilities

$23M

Stockholders' Equity

$158M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$14M	-$6M	-148.0%
Net Income	-$11M	-$5M	-105.9%